Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose or a recommended dose of
oral AP24534 in a defined schedule in patients with refractory or advanced chronic
myelogenous leukemia and other refractory hematologic malignancies.